Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology
<p><b>Aims</b></p> Cardiovascular disease is the most common cause of mortality and morbidity in the world, but the pharmaceutical industry's willingness to invest in this field has declined because of the many challenges involved with bringing new cardiovascular drugs t...
Main Authors: | Jackson, N, Atar, D, Borentain, M, Breithardt, G, van Eickels, M, Endres, M, Fraass, U, Friede, T, Hannachi, H, Janmohamed, S, Kreuzer, J, Landray, M, Lautsch, D, Le Floch, C, Mol, P, Naci, H, Samani, NJ, Svensson, A, Thorstensen, C, Tijssen, J, Vandzhura, V, Zalewski, A, Kirchhof, P |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Oxford University Press
2015
|
Similar Items
-
Niacin for reduction of cardiovascular risk.
by: Landray, M, et al.
Published: (2014) -
Niacin for reduction of cardiovascular risk.
by: Landray, M, et al.
Published: (2014) -
Renal function: an emerging risk factor for cardiovascular disease?
by: Landray, M, et al.
Published: (2001) -
Homocysteine, renal function, and risk of cardiovascular disease.
by: Clarke, R, et al.
Published: (2003) -
Which cardiovascular risk factors matter in chronic kidney disease?
by: Baigent, C, et al.
Published: (2007)